AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deOCT 233 min read$EVAX

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported 3-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The trial showed 89% of vaccine neoantigens generated specific T-cell responses, with sustained immune and clinical responses. The data will be presented at the ESMO 2026 Congress. Evaxion maintains a cash runway into 2027.

Original reporting
finanznachrichten.de
Published Oct 23, 2026, 6:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 7:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$EVAXBullishHigh
01

Why it matters

The three‑year follow‑up confirms durable immune responses and disease control, strengthening the company's pipeline credibility and likely prompting a price increase.

02

Market read

First‑time disclosure of robust Phase 2 data for a personalized cancer vaccine, a material catalyst for EVAX and potentially for the AI‑immunology sector.

03

What to watch

Cash runway extends only to H2 2027; financing needs may limit long‑term upside.

Relevance 8/10Novelty 9/10Timing: today

Background

Evaxion A/S (NASDAQ: EVAX) is a Copenhagen‑based clinical‑stage TechBio firm developing personalized cancer vaccines using its AI‑Immunology platform.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion disclosed three-year Phase 2 trial data showing 89% target precision and durable T‑cell responses in advanced melanoma patients.

Expected impact

upward pressure as the market prices in the strong efficacy and durability data.

Evidence & confidence

Phase 2 data with high response rates and no tumor progression is material for a clinical‑stage biotech and often triggers a price rally.

Market effects

Sector

May lift other AI‑driven immunotherapy peers as the platform gains validation.

Regional

European biotech indices could see modest gains.

Global

Adds credibility to AI‑based vaccine design, potentially influencing global biotech investment flows.

Counterpoint

What could challenge this read

If the data does not translate to Phase 3 success, the rally could be short‑lived.

Key entities

  • company
    Evaxion A/S

    Clinical‑stage biotech developing personalized cancer vaccines.

  • company
    Merck & Co., Inc.

    Provider of anti‑PD‑1 therapy (Keytruda) used in the trial.

Read at source← All news

StoryEvaxion reports durable three-year EVX-01 melanoma vaccine results

Also covered by

1 outlet

Related articles

OCT 23
$EVAXMedAI 8/10

Evaxion reports three-year data for cancer vaccine EVX-01

Evaxion A/S (EVAX) reported three-year phase 2 trial data for its cancer vaccine EVX-01, showing sustained immune response and no tumor progression in advanced melanoma patients. The data will be presented at the ESMO Congress 2026. EVX-01 is personalized and designed using Evaxion's AI-Immunology platform. The company has a cash runway into mid-2027.

investing.com2 min
OCT 23
$EVAXMedAI 9/10

Six melanoma responders received Evaxion's vaccine alone in year three. None had tumor progression.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

stocktitan.net2 min
OCT 19
$EVAXHighAI 8/10

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion AS ADR (EVAX) shares rose 21.6% after reporting 3-year data from its EVX-01 phase 2 trial in advanced melanoma patients. All patients maintained clinical responses with no tumor progression. The data will be presented at ESMO Congress 2026. EVX-01 is a personalized cancer vaccine developed using AI-Immunology platform.

investing.com2 min
OCT 19
$EVAXMedAI 8/10

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported sustained clinical responses for all patients at three-year follow-up in a phase 2 trial for its personalized cancer vaccine EVX-01 in advanced melanoma. The data, to be presented at ESMO 2026, showed a 75% objective response rate with 25% of patients achieving complete response. EVX-01 will be discussed in a webinar and poster session.

finanznachrichten.de2 min